噻唑烷二酮类药物与骨质疏松

被引：4

作者：

鲁郡 ^{[1
]}

顾明君 ^{[2
]}

机构：

[1] 上海市浦东新区公利医院内分泌科

[2] 第二军医大学附属长征医院内分泌科

来源：

临床荟萃 | 2011年 / 26卷 / 01期

关键词：

骨质疏松; 噻唑烷二酮; 成骨细胞; 破骨细胞;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

引用

页码：79 / 82

页数：4

共 12 条

[1]

Thiazolidinedione Use and the Longitudinal Risk of Fractures in Patients with Type 2 Diabetes Mellitus [J].

Habib, Zeina A. ;

Havstad, Suzanne L. ;

Wells, Karen ;

Divine, George ;

Pladevall, Manel ;

Williams, L. Keoki .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (02) :592-600

[2]

The effect of thiazolidinediones on bone mineral density in Chinese older patients with type 2 diabetes [J].

Li, Hong ;

Cui, Ran ;

Cai, Haidong ;

Wu, Guoting ;

Lv, Zhongwei ;

Sheng, Chunjun ;

Cheng, Xiaoyun ;

Li, Fang ;

Yu, Yongchun .

JOURNAL OF BONE AND MINERAL METABOLISM, 2010, 28 (01) :77-81

[3]

Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line; but not through the peroxisome proliferator-activated receptor- γ pathway.[J].Shao-Hung Hung;Ching-Hua Yeh;Hsuan-Ti Huang;Peihua Wu;Mei-Ling Ho;Chung-Hwan Chen;Chihuei Wang;David Chao;Gwo-Jaw Wang.Life Sciences.2008, 11

[4]

Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells [J].

Benvenuti, S. ;

Cellai, I. ;

Luciani, P. ;

Deledda, C. ;

Baglioni, S. ;

Giuliani, C. ;

Saccardi, R. ;

Mazzanti, B. ;

Dal Pozzo, S. ;

Mannucci, E. ;

Peri, A. ;

Serio, M. .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2007, 30 (09) :RC26-RC30

[5]

Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women [J].

Berberoglu, Zehra ;

Gursoy, Alptekin ;

Bayraktar, Nilufer ;

Yazici, Ayse Canan ;

Tutuncu, Neslihan Bascil ;

Demirag, Nilgun Guvener .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09) :3523-3530

[6]

Skeletal consequences of thiazolidinedione therapy [J].

Grey, A. .

OSTEOPOROSIS INTERNATIONAL, 2008, 19 (02) :129-137

[7]

PPARγ inhibits osteogenesis via the down-regulation of the expression of COX-2 and iNOS in rats.[J].Tzu-Hung Lin;Rong-Sen Yang;Chih-Hsin Tang;Chih-Peng Lin;Wen-Mei Fu.Bone.2007, 4

[8]

The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women:: A randomized, controlled trial [J].